Novozymes Showcases Biopharmaceutical Solutions at BioProcess International 2010
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Novozymes Biopharma, part of Novozymes A/S will be showcasing its portfolio of biopharmaceutical technologies and solutions at booth #507 and #509 at the 2010 BioProcess International Conference and Exhibition, 20-24 September at Rhode Island Convention Center, Providence, RI, USA.
The annual conference and exhibition aims to accelerate and improve biopharmaceutical processes and product development, attracting key personnel from across the bioprocessing industry. At this year's event Novozymes' booth will feature the company's range of regulatory compliant, recombinant and animal-free products and technologies.
During the five day conference, Novozymes will be presenting two technical posters entitled "Albumin: A robust pharmaceutical excipient in the stabilization of protein therapeutics' and "Application of animal-free recombinant bioactive protein supplements to improve the performance of cell-based viral vaccine production". In addition the company will deliver a presentation on the "Impact of recombinant albumin on the stability of a malarial antigen vaccine".
Novozymes will also be hosting a workshop on "Improving biomanufacturing efficiency through recombinant solutions". Company experts will discuss how the introduction of innovative technologies and products and ongoing collaborative dialog with the biomanufacturing industry are driving efficiency improvements across the biopharmaceutical lifecycle.
The company will also be discussing its recent announcement of a 10-year extension to its joint agreement with SAFC, a member of the Sigma-Aldrich Group. The renewal sees SAFC retain exclusive marketing and distribution rights for Novozymes' LONG R³IGF-I (LONGR3) growth factor.
The annual conference and exhibition aims to accelerate and improve biopharmaceutical processes and product development, attracting key personnel from across the bioprocessing industry. At this year's event Novozymes' booth will feature the company's range of regulatory compliant, recombinant and animal-free products and technologies.
During the five day conference, Novozymes will be presenting two technical posters entitled "Albumin: A robust pharmaceutical excipient in the stabilization of protein therapeutics' and "Application of animal-free recombinant bioactive protein supplements to improve the performance of cell-based viral vaccine production". In addition the company will deliver a presentation on the "Impact of recombinant albumin on the stability of a malarial antigen vaccine".
Novozymes will also be hosting a workshop on "Improving biomanufacturing efficiency through recombinant solutions". Company experts will discuss how the introduction of innovative technologies and products and ongoing collaborative dialog with the biomanufacturing industry are driving efficiency improvements across the biopharmaceutical lifecycle.
The company will also be discussing its recent announcement of a 10-year extension to its joint agreement with SAFC, a member of the Sigma-Aldrich Group. The renewal sees SAFC retain exclusive marketing and distribution rights for Novozymes' LONG R³IGF-I (LONGR3) growth factor.
